Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
10’654.00 GBX | +0.34% | +0.40% | +0.51% |
Voraussichtliche Gewinn- und Verlustrechnung: AstraZeneca PLC
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Umsatz 1 | 24’384 | 26’617 | 37’417 | 44’351 | 45’811 | 53’075 | 56’960 | 60’257 |
Veränderung | - | 9.16% | 40.58% | 18.53% | 3.29% | 15.86% | 7.32% | 5.79% |
EBITDA 1 | 6’686 | 8’311 | 7’586 | 9’237 | 13’580 | 17’061 | 20’062 | 22’023 |
Veränderung | - | 24.3% | -8.72% | 21.76% | 47.02% | 25.64% | 17.58% | 9.78% |
Betriebsergebnis (EBIT) 1 | 6’436 | 7’340 | 9’928 | 13’350 | 14’534 | 17’021 | 19’093 | 21’004 |
Veränderung | - | 14.05% | 35.26% | 34.47% | 8.87% | 17.11% | 12.17% | 10.01% |
Gezahlte Zinsen 1 | -765 | -782 | -862 | -1’251 | -1’282 | -1’186 | -964.8 | -945.7 |
Gewinn vor Steuern (EBT) 1 | 1’548 | 3’916 | -265 | 2’501 | 6’899 | 10’661 | 13’210 | 15’162 |
Veränderung | - | 152.97% | - | - | 175.85% | 54.53% | 23.91% | 14.77% |
Nettoergebnis 1 | 1’335 | 3’196 | 112 | 3’288 | 5’961 | 8’361 | 10’147 | 11’644 |
Veränderung | - | 139.4% | -96.5% | 2’835.71% | 81.3% | 40.26% | 21.36% | 14.76% |
Datum der Veröffentlichung | 14.02.20 | 11.02.21 | 10.02.22 | 09.02.23 | 08.02.24 | - | - | - |
Vorläufige Bilanz: AstraZeneca PLC
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoverschuldung 1 | 12’009 | 11’867 | 24’383 | 22’923 | 22’510 | 22’617 | 17’008 | 9’335 |
Veränderung | - | -1.18% | 105.47% | -5.99% | -1.8% | 0.48% | -24.8% | -45.11% |
Datum der Veröffentlichung | 14.02.20 | 11.02.21 | 10.02.22 | 09.02.23 | 08.02.24 | - | - | - |
Prognostizierter Cashflow: AstraZeneca PLC
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX Investitionsaufwand 1 | 979 | 961 | 1’091 | 1’091 | 1’361 | 2’016 | 2’114 | 2’161 |
Veränderung | - | -1.84% | 13.53% | 0% | 24.75% | 48.12% | 4.88% | 2.2% |
Free Cashflow (FCF) 1 | 1’990 | 3’838 | 4’872 | 8’717 | 8’984 | 7’092 | 11’595 | 13’598 |
Veränderung | - | 92.86% | 26.94% | 78.92% | 3.06% | -21.06% | 63.49% | 17.28% |
Datum der Veröffentlichung | 14.02.20 | 11.02.21 | 10.02.22 | 09.02.23 | 08.02.24 | - | - | - |
Voraussichtliche Finanzkennzahlen: AstraZeneca PLC
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Rentabilität | ||||||||
EBITDA-Marge (%) | 27.42% | 31.22% | 20.27% | 20.83% | 29.64% | 32.15% | 35.22% | 36.55% |
EBIT-Marge (%) | 26.39% | 27.58% | 26.53% | 30.1% | 31.73% | 32.07% | 33.52% | 34.86% |
EBT-Marge (%) | 6.35% | 14.71% | -0.71% | 5.64% | 15.06% | 20.09% | 23.19% | 25.16% |
Nettogewinn (%) | 5.47% | 12.01% | 0.3% | 7.41% | 13.01% | 15.75% | 17.81% | 19.32% |
FCF-Marge N (%) | 8.16% | 14.42% | 13.02% | 19.65% | 19.61% | 13.36% | 20.36% | 22.57% |
FCF / Nettogewinn (%) | 149.06% | 120.09% | 4’350% | 265.12% | 150.71% | 84.82% | 114.27% | 116.78% |
Rentabilität | ||||||||
ROA | 2.19% | 4.99% | 8.77% | 3.26% | 11.48% | 9.44% | 10.99% | 12.03% |
ROE | 35.58% | 36.72% | 27.51% | 27.23% | 29.77% | 30.35% | 31.22% | 31.17% |
Finanzielle Gesundheit | ||||||||
Verschuldungsgrad (Verbindlichkeiten/EBITDA) | 1.8x | 1.43x | 3.21x | 2.48x | 1.66x | 1.33x | 0.85x | 0.42x |
Verschuldung / Free Cashflow | 6.03x | 3.09x | 5x | 2.63x | 2.51x | 3.19x | 1.47x | 0.69x |
Kapitalintensität | ||||||||
CAPEX / Umsatz (%) | 4.01% | 3.61% | 2.92% | 2.46% | 2.97% | 3.8% | 3.71% | 3.59% |
CAPEX / EBITDA (%) | 14.64% | 11.56% | 14.38% | 11.81% | 10.02% | 11.82% | 10.54% | 9.81% |
CAPEX / FCF (%) | 49.2% | 25.04% | 22.39% | 12.52% | 15.15% | 28.43% | 18.24% | 15.89% |
Elemente pro Aktie | ||||||||
Cashflow pro Aktie 1 | 2.282 | 3.655 | 4.179 | 6.287 | 6.623 | 8.271 | 10.29 | 11.55 |
Veränderung | - | 60.17% | 14.33% | 50.46% | 5.34% | 24.88% | 24.39% | 12.27% |
Dividende pro Aktie 1 | 2.8 | 2.8 | 2.87 | 2.9 | 2.9 | 3.105 | 3.271 | 3.427 |
Veränderung | - | 0% | 2.5% | 1.05% | 0% | 7.05% | 5.35% | 4.77% |
Buchwert je Aktie 1 | 10.09 | 11.91 | 27.69 | 23.93 | 25.06 | 26.78 | 29.91 | 34.08 |
Veränderung | - | 18.04% | 132.51% | -13.6% | 4.74% | 6.87% | 11.67% | 13.96% |
Gewinn pro Aktie 1 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 5.43 | 6.579 | 7.566 |
Veränderung | - | 136.89% | -96.72% | 2’537.5% | 80.57% | 42.51% | 21.16% | 15% |
Anz. der Aktien (in Tausend) | 1’311’913 | 1’312’660 | 1’549’159 | 1’549’528 | 1’549’926 | 1’550’287 | 1’550’287 | 1’550’287 |
Datum der Veröffentlichung | 14.02.20 | 11.02.21 | 10.02.22 | 09.02.23 | 08.02.24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
KGV | 25x | 20.6x |
KBV | 5.07x | 4.54x |
EV / Sales | 4.39x | 3.99x |
Rendite | 2.29% | 2.41% |
Gewinn pro Aktie & Dividende
Historische Entwicklung KGV
Entwicklung der Dividendenrendite
Quartalsumsätze - Abweichungsrate
- Börse
- Aktien
- 886455 Aktie
- Finanzen AstraZeneca PLC
MarketScreener is also available in this country: United States.
Switch edition